Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 1
2013 2
2014 4
2015 5
2016 4
2017 5
2018 6
2019 4
2020 4
2021 5
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Adverse Event by CTCAE v4 Severity Grade"
Page 1
Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers.
Villa A, Vollemans M, De Moraes A, Sonis S. Villa A, et al. Support Care Cancer. 2021 Oct;29(10):6061-6068. doi: 10.1007/s00520-021-06177-x. Epub 2021 Mar 31. Support Care Cancer. 2021. PMID: 33788003 Clinical Trial.
The lack of a single grading scale compounds outcome interpretation. Consequently, we assessed the concordance of three of the most commonly used OM grading criteria (World Health Organization (WHO), Radiation Therapy Oncology Group (RTOG), and the common terminolog …
The lack of a single grading scale compounds outcome interpretation. Consequently, we assessed the concordance of three of the most c …
Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort.
Hudson MM, Ehrhardt MJ, Bhakta N, Baassiri M, Eissa H, Chemaitilly W, Green DM, Mulrooney DA, Armstrong GT, Brinkman TM, Klosky JL, Krull KR, Sabin ND, Wilson CL, Huang IC, Bass JK, Hale K, Kaste S, Khan RB, Srivastava DK, Yasui Y, Joshi VM, Srinivasan S, Stokes D, Hoehn ME, Wilson M, Ness KK, Robison LL. Hudson MM, et al. Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):666-674. doi: 10.1158/1055-9965.EPI-16-0812. Epub 2016 Dec 29. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 28035022 Free PMC article. Review.
Characterization of toxicity associated with cancer and its treatment is essential to quantify risk, inform optimization of therapeutic approaches for newly diagnosed patients, and guide health surveillance recommendations for long-term survivors. The NCI Common Terminology Crite …
Characterization of toxicity associated with cancer and its treatment is essential to quantify risk, inform optimization of therapeutic appr …
Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Hsu HT, Yu CC, Lee YH, Chan JC, Chu CY. Hsu HT, et al. Support Care Cancer. 2022 Nov;30(11):9211-9219. doi: 10.1007/s00520-022-07347-1. Epub 2022 Sep 3. Support Care Cancer. 2022. PMID: 36056941
METHODS: This was a cross-sectional study including 132 non-small-cell lung cancer (NSCLC) patients treated with gefitinib, erlotinib, afatinib, or osimertinib in Taiwan. The severity level of dAEs was graded by NCI-CTCAE v4.03 and PRO-CTCAE ITE …
METHODS: This was a cross-sectional study including 132 non-small-cell lung cancer (NSCLC) patients treated with gefitinib, erlotinib, afati …
Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A, Modi M, Prakash G, Malhotra P, Khadwal A, Jain S, Kumari S, Varma N, Varma S. Lakshman A, et al. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):513-519.e1. doi: 10.1016/j.clml.2017.06.035. Epub 2017 Jul 6. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28842138
Most investigators use the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). PATIENTS AND METHODS: We prospectively evaluated the incidence of BiPN in treatment-naive patients with MM receiving weekly cyclophosphamide, bort …
Most investigators use the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). PATIEN …
Taxane-induced peripheral neuropathy and quality of life in breast cancer patients.
Salehifar E, Janbabaei G, Alipour A, Tabrizi N, Avan R. Salehifar E, et al. J Oncol Pharm Pract. 2020 Sep;26(6):1421-1428. doi: 10.1177/1078155219898511. Epub 2020 Jan 14. J Oncol Pharm Pract. 2020. PMID: 31937190
The criteria of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03) and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30, version 3.0) were used to eval …
The criteria of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03) and t …
Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial).
Robijns J, Lodewijckx J, Claes S, Van Bever L, Pannekoeke L, Censabella S, Bussé L, Colson D, Kaminski I, Broux V, Puts S, Vanmechelen S, Timmermans A, Noé L, Bulens P, Govers M, Maes A, Mebis J. Robijns J, et al. Radiother Oncol. 2021 May;158:268-275. doi: 10.1016/j.radonc.2021.03.002. Epub 2021 Mar 10. Radiother Oncol. 2021. PMID: 33711412 Free article. Clinical Trial.
The severity of skin reactions was assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v4.03) and the Radiotherapy-Induced Skin Reaction Assessment Scale (RISRAS). Quality of life (QoL …
The severity of skin reactions was assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events …
Extent of extravasation: Patients on parenteral plant alkaloids.
Somayaji S, Reddy SS, Murthy MK, Maka VV. Somayaji S, et al. J Cancer Res Ther. 2023 Jan 1;19(Suppl 2):S841-S844. doi: 10.4103/jcrt.JCRT_457_19. Epub 2023 Dec 15. J Cancer Res Ther. 2023. PMID: 38384064 Free article.
BACKGROUND: Plant alkaloids remain an essential part of many chemotherapeutic regimens. Although many adverse effects have been studied with appropriate management guidelines, extravasation (EV) is one adverse event that is yet to be studied at a regional sca …
BACKGROUND: Plant alkaloids remain an essential part of many chemotherapeutic regimens. Although many adverse effects have been studi …
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Verzoni E, et al. J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. J Immunother Cancer. 2019. PMID: 30944023 Free PMC article.
Pts included in the analysis had received 1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cu …
Pts included in the analysis had received 1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using …
Patient-Reported Outcome Measures and Dosimetric Correlates for Early Detection of Acute Radiation Therapy-Related Esophagitis.
Voong KR, Han P, Hales R, Hill C, Friedes C, McNutt T, Lee S, Snyder C. Voong KR, et al. Pract Radiat Oncol. 2021 May-Jun;11(3):185-192. doi: 10.1016/j.prro.2020.10.009. Epub 2020 Oct 31. Pract Radiat Oncol. 2021. PMID: 33137465
Weekly, patients reported difficulty swallowing (patient-reported outcome version of the Common Terminology Criteria for Adverse Events [PRO-CTCAE] v.1: 0-none, 1-mild, 2-moderate, 3-severe, 4-very severe). Physicians graded dysphagia ( …
Weekly, patients reported difficulty swallowing (patient-reported outcome version of the Common Terminology Criteria for Adverse E …
Evaluation of the efficacy of the anti-ulcer oral mucosal protective agent RADoralex® in the prevention and treatment of radiation-induced oral mucosal reactions induced during treatment of nasopharyngeal carcinoma.
Yin J, Xie J, Lin J, Weng C, Lu S, Xu P, Zhang S, Luo C, Huang Y, Li L, Lang J, Feng M. Yin J, et al. Cancer Biol Ther. 2022 Dec 31;23(1):27-33. doi: 10.1080/15384047.2021.2013704. Epub 2022 Jan 6. Cancer Biol Ther. 2022. PMID: 34989325 Free PMC article. Clinical Trial.
A total of 90 patients with locally advanced NPC who developed post-treatment grade 1 oral mucositis were selected for this study. They were randomly assigned to the experimental group (n = 44) treated by mouth rinsing with the RADoralex during radiochemotherapy and …
A total of 90 patients with locally advanced NPC who developed post-treatment grade 1 oral mucositis were selected for this study. Th …
40 results